Immunology and Bi...
Follow
Find
4.9K views | +10 today
 
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent ... - MENAFN.COM

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent ...
MENAFN.COM
This is thefourth country to issue this patent as a result of the ExpeditedPatent Allowance Program which follows the issuance of U.S.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stem cell-based therapies for cancer treatment: separating hope from hype : Nature Reviews Cancer : Nature Publishing Group

Stem cell-based therapies for cancer treatment: separating hope from hype : Nature Reviews Cancer : Nature Publishing Group | Immunology and Biotherapies | Scoop.it
Stem cell-based therapies for cancer treatment: separating hope from hype http://t.co/CEJdp0kMq7
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models

Autologous apoptotic cells preceding transplantation enhance survival in lethal murine... http://t.co/izjE7Fko7i #bloodTCB
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine

Novel helper epitope peptides of Survivin cancer antigen identified in Immunology Letters research: on #ScienceDirect http://t.co/NKwcwKTD7t
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Infection with Host-Range Mutant Adenovirus 5 Suppr... [PLoS One. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

MD Anderson Scientists Find Novel Immunotherapy/Vaccine Combo Decreases ... - BioNews Texas

MD Anderson Scientists Find Novel Immunotherapy/Vaccine Combo Decreases ... - BioNews Texas | Immunology and Biotherapies | Scoop.it
BioNews Texas
MD Anderson Scientists Find Novel Immunotherapy/Vaccine Combo Decreases ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from PARP Inhibitors Cancer Review
Scoop.it!

(Cancer) Drug Costs: How high can they go?

(Cancer) Drug Costs: How high can they go? | Immunology and Biotherapies | Scoop.it

The first of a promising new class of cancer drugs went on sale in Japan this week at an average annual cost of $143,000 a patient, a harbinger of hefty prices the new drugs are expected to command in the U.S.and Europe in coming months.  Bristol-Myers, which plans to market nivolumab in the U.S. if the FDA clears it for sale, declined to say how much it will charge. A spokeswoman said the company prices its medicines based on “the value they deliver to patients and society, the scientific innovation they represent and the investment required to support” drug research-and-development.

 

Higher prices for new cancer drugs have become an increasing concern for patients and their families, who often shoulder high copayments. At the same time, the PD-1 drugs “have the potential to be game-changers for a lot of people” because patients in studies have had “meaningful, long-term responses” to the drugs. PD-1 targeting drugs have shown strong cancer-fighting results in clinical trials.

 

Bristol-Myers, which plans to market nivolumab in the U.S. if the FDA clears it for sale, declined to say how much it will charge. A spokeswoman said the company prices its medicines based on “the value they deliver to patients and society, the scientific innovation they represent and the investment required to support” drug research-and-development. Bristol-Myers has been marketing another kind of cancer immunotherapy, Yervoy, as a melanoma treatment in the U.S. since 2011 at a cost of $120,000 a patient for a standard, complete course of treatment.


Via Pharma Guy, Krishan Maggon
more...
Pharma Guy's curator insight, September 5, 1:03 PM


On Quora, I posted the question: "How close are the pharmaceutical companies to "curing" cancer?" (see here) and got some interesting feedback. Dan Munro (@danmunro), Founder / CEO - iPatient, had this to say:


"While curing a given cancer is clearly a worthwhile goal - it is often not the primary focus - and early detection is still the leading indicator of successfully treating all cancers. Some cancers are simply pushed so far into remission that you're more likely to die of a different cancer or old age in your sleep. It's not a technical cure - but it's a practical one.

"The sad reality is this: The death rate for cancer (adjusted for the size and age of the population) has dropped only 5% from 1950 to 2005 (see here). 


So, (1) the reality is that the death rate for cancer hasn't improved very much in the past 50 years, and (2) pharma's little "pills" haven't contributed much to that statistic. Shame on Bayer for taking credit where none is due!

Krishan Maggon 's curator insight, September 5, 7:07 PM

High cost of new life saving cancer and HCV drugs. Increasing safety and efficacy bar means limited chances of success and higher costs for the pharma biotech industry due to regulatory burden.

Refadoc.com's curator insight, September 9, 7:54 AM

http://www.refadoc.com/tag/cancer

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

FDA Approves Merck's PD-1 Inhibitor, Keytruda

FDA Approves Merck's PD-1 Inhibitor, Keytruda | Immunology and Biotherapies | Scoop.it
Following the approval in Japan of BMS's nivolumab (Opdivo), Merck's Keytruda becomes the first PD-1 targeting cancer immunotherapy to earn FDA's nod.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Transplantation-induced cancers: Emerging evi... [Oncoimmunology. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Gilbert Faure au nom de l'ASSIM's insight:

Recent reassessments have revealed insights into causal factors, primarily centering on modulations of the natural killer (NK) cell compartment in liver transplant recipients. In the presence of cytomegalovirus, the clonal expansion of differentiated NK cells could restrict the diversity of the NK repertoire favoring the development of certain tumors.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Artificial Antibodies To Treat Lung Cancer - Asian Scientist Magazine

Artificial Antibodies To Treat Lung Cancer - Asian Scientist Magazine | Immunology and Biotherapies | Scoop.it
Asian Scientist Magazine
Artificial Antibodies To Treat Lung Cancer
Asian Scientist Magazine
Antibody-based therapeutics make up the majority of drugs on trial today, attracting the lions share of investment.
Gilbert Faure au nom de l'ASSIM's insight:

IL-6

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

EC Designates Innate's CTCL Antibody As Orphan Drug - BioResearch Online (press release)

EC Designates Innate's CTCL Antibody As Orphan Drug - BioResearch Online (press release) | Immunology and Biotherapies | Scoop.it
EC Designates Innate's CTCL Antibody As Orphan Drug BioResearch Online (press release) Innate Pharma, a biopharmaceutical company developing innate immunity drug candidates, announced that the European Commission has awarded Orphan Medicinal...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

The human application of gene therapy to re-pr... [Chin J Cancer. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

US Patent Issued to CytoDyn on Sept. 2 for "Methods for Inhibiting HIV-1 Replication Involving the Administration of an Anti-CCR5 Receptor Monoclonal Antibody and Small Molecule CCR5 Receptor Antag...

ALEXANDRIA, Va., Sept. 2 -- United States Patent no. 8,821,877, issued on Sept. 2, was assigned...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Artificial spleen cleans up blood

Artificial spleen cleans up blood | Immunology and Biotherapies | Scoop.it
Device improves survival in rats after severe infections.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis

Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis | Immunology and Biotherapies | Scoop.it
by Jun-Xia Cao, Xiao-Yan Zhang, Jin-Long Liu, Duo Li, Jun-Li Li, Yi-Shan Liu, Min Wang, Bei-Lei Xu, Hai-Bo Wang, Zheng-Xu Wang
Background The effectiveness of immunotherapy for high-grade glioma (HGG) patients remains controversial.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Targeting DNGR-1 (CLEC9A) with antibody/MUC1 p... [Eur J Immunol. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Advanced Cell Technology wins US patent for dendritic cell manufacturing process - BioPharma-Reporter.com

Advanced Cell Technology wins US patent for dendritic cell manufacturing process - BioPharma-Reporter.com | Immunology and Biotherapies | Scoop.it
Advanced Cell Technology wins US patent for dendritic cell manufacturing process BioPharma-Reporter.com Regenerative medicine company Advanced Cell Technology (ACT) has been issued a US patent from the US Patent and Trademark Office covering...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Belgian receives research grant from Jeffrey Modell to help cure IPEX syndrome

Belgian receives research grant from Jeffrey Modell to help cure IPEX syndrome | Immunology and Biotherapies | Scoop.it
For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Mersana Strengthens Antibody-Drug Conjugate Intellectual Property Position with Issuance of Three Additional U.S. Patents | EON: Enhanced Online News

Mersana Strengthens Antibody-Drug Conjugate Intellectual Property Position with Issuance of Three Additional U.S. Patents | EON: Enhanced Online News | Immunology and Biotherapies | Scoop.it
Mersana Therapeutics has announced the USPTO granted patents that strengthen protections for Mersana's internal pipeline of Fleximer antibody-drug con (Mersana Strengthens Antibody-Drug Conjugate Intellectual Property Position with Issuance of...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Notebook
Scoop.it!

Cancer Immunology Essentials

Cancer Immunology Essentials | Immunology and Biotherapies | Scoop.it

Cancer Immunology Essentials is a valuable online educational resource for students, researchers, physicians, and clinicians working in the field of cancer research who wish to learn more about the rapidly-evolving fields of cancer immunology and immunotherapy

more...
Gilbert Faure au nom de l'ASSIM's curator insight, September 9, 3:55 AM

an evolving resource for a rapidly evolving field

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Novavax, Inc. : Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC | 4-Traders

Novavax, Inc. : Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC | 4-Traders | Immunology and Biotherapies | Scoop.it
GAITHERSBURG, Md., Sept. 6, 2014 -- Novavax, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle... | September 6, 2014 (Novavax, Inc.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Arsanis Biosciences Is Fighting The Nastiest Bacteria With Monoclonal Antibodies - Life Science Leader Magazine

Arsanis Biosciences Is Fighting The Nastiest Bacteria With Monoclonal Antibodies - Life Science Leader Magazine | Immunology and Biotherapies | Scoop.it
Arsanis Biosciences Is Fighting The Nastiest Bacteria With Monoclonal Antibodies Life Science Leader Magazine “I developed the idea of using monoclonal antibodies, which are very successful in the cancer and in the autoimmunity areas, in the new...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Leaders of the Antibody sector: An interview with Steve Sazinsky - Total Biopharma : Total Biopharma

Leaders of the Antibody sector: An interview with Steve Sazinsky - Total Biopharma : Total Biopharma | Immunology and Biotherapies | Scoop.it
An interview with Steve Sazinsky, Jounce Therapeutics and Total Biopharma blog about the latest antibody industry challenges and developments.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Patent watch: Stelara safe after IL-12 antibody dispute - Nature.com

Patent watch: Stelara safe after IL-12 antibody dispute Nature.com AbbVie has lost a patent dispute in which it tried to show that Janssen's Stelara (ustekinumab) — an antibody binding to interleukin-12 (IL-12) and IL-23 that is marketed for the...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy : Nature Communications : Nature Publishing Group

Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy : Nature Communications : Nature Publishing Group | Immunology and Biotherapies | Scoop.it
RT @Science_Reddit: How autoimmune diseases (like MS) may be treated with antigen-specific immunotherapy http://t.co/qBjqaQx2R7
more...
Krishan Maggon 's curator insight, September 7, 8:35 AM

open access

 

Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapyBronwen R. Burton,Graham J. Britton,Hai Fang,Johan Verhagen,Ben Smithers,Catherine A. Sabatos-Peyton,Laura J. Carney,Julian Gough,Stephan Strobel& David C. WraithAffiliationsContributionsCorresponding authorNature Communications 5, Article number: 4741 doi:10.1038/ncomms5741Received 03 April 2014 Accepted 18 July 2014 Published 03 September 2014
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal ... - NASDAQ

Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal ... - NASDAQ | Immunology and Biotherapies | Scoop.it
Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal ...
more...
No comment yet.